This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BLU BELLUS Health (BLU) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About BELLUS Health Stock (NASDAQ:BLU) 30 days 90 days 365 days Advanced Chart Remove Ads Get BELLUS Health alerts:Sign Up Key Stats Today's Range$14.74▼$14.7550-Day Range$14.42▼$14.7552-Week Range$6.38▼$14.76Volume3.45 million shsAverage Volume3.08 million shsMarket Capitalization$1.87 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.Read More… Remove Ads Receive BLU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter. Email Address BLU Stock News HeadlinesHighmark Bright Blue Futures Awards celebrate champions of health equityNovember 11, 2024 | bizjournals.comBlue Cross Blue Shield agrees to pay $2.8 billion to settle US health provider class actionOctober 14, 2024 | msn.comTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 4, 2025 | Porter & Company (Ad)Blue Cross Blue Shield Settles US Health Provider Class Action for $2.8 BillionOctober 14, 2024 | msn.comBlue Cross Blue Shield agrees to pay $2.8 bln to settle US health provider class actionOctober 14, 2024 | reuters.comWhich Florida Blue members, Baptist Health patients can expect changes in coverage?October 3, 2024 | yahoo.comSome Florida Blue policyholders will lose all or some access to Baptist Health providersOctober 3, 2024 | yahoo.comBlue Plus Named First HMO in Minnesota to Receive NCQA Health Equity Plus AccreditationOctober 1, 2024 | markets.businessinsider.comSee More Headlines BLU Stock Analysis - Frequently Asked Questions How were BELLUS Health's earnings last quarter? BELLUS Health Inc. (NASDAQ:BLU) posted its earnings results on Wednesday, November, 10th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.07. BELLUS Health had a negative net margin of 578,586.63% and a negative trailing twelve-month return on equity of 24.27%. What other stocks do shareholders of BELLUS Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that BELLUS Health investors own include NIO (NIO), Meta Platforms (META), Pfizer (PFE), Sorrento Therapeutics (SRNE), Alibaba Group (BABA), Tesla (TSLA) and Ford Motor (F). Company Calendar Last Earnings11/10/2021Today4/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:BLU CIK1259942 Webwww.bellushealth.com Phone(450) 680-4500Fax45-0680-4501Employees74Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,080,000.00 Net Margins-578,586.63% Pretax Margin-578,226.56% Return on Equity-24.27% Return on Assets-23.14% Debt Debt-to-Equity RatioN/A Current Ratio33.42 Quick Ratio33.42 Sales & Book Value Annual Sales$15,000.00 Price / Sales124,613.93 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book4.77Miscellaneous Outstanding Shares126,812,000Free Float96,162,000Market Cap$1.87 billion OptionableNot Optionable Beta0.19 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:BLU) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BELLUS Health Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BELLUS Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.